Hrain Biotechnology

Hrain Biotechnology, based in Shanghai, China, is a biotechnology company focusing on the development and production of healthcare and agricultural products, including diagnostic reagents and biopharmaceuticals. Founded in 2015, Hrain Biotechnology specializes in creating innovative biotechnology solutions. The company is headquartered in Shanghai, China. It has successfully completed four deals, with a notable funding round being Series B, where it raised CNY 200.

000 mn from investors including Junchenda Capital and K. WAH Group on April 26, 2021. The CEO of the company is Fei Huang. Hrain Biotechnology specializes in the development and production of biotechnology products tailored for healthcare and agricultural sectors.

Its primary offerings consist of advanced diagnostic reagents and devices focused on precise disease detection, alongside biopharmaceutical products aimed at enhancing therapeutic outcomes. The company serves a diverse clientele, which includes hospitals, laboratories, and agricultural enterprises, addressing essential challenges in disease management and crop yield optimization. With a global presence in North America and Asia, Hrain Biotechnology ensures that its innovative solutions are readily accessible to a wide range of end users. Hrain Biotechnology generates revenue through direct sales to healthcare providers and partnerships with distributors across various markets.

Transactions occur through a combination of B2B agreements and direct-to-consumer sales, allowing the company to reach its target sectors effectively. The company offers flagship products, such as proprietary diagnostic kits and treatment solutions, under various pricing plans that accommodate both bulk buyers and individual consumers, fostering long-term relationships with key stakeholders in the biotechnology field. Hrain Biotechnology is actively designing new products and plans to launch them in the near future. The company aims to expand into new geographic regions, with specific targets set for North America and Southeast Asia by the end of 2023.

The recent funding of CNY 200. 000 mn from the Series B round will support these growth initiatives, enhancing the company's ability to innovate and reach wider markets.